Deutsche Bank’s Acumen Pharmaceuticals ABOS Stock Holding History

Deutsche Bank’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-96,995	Closed	-$107K	–	3601
2025 Q1	$107K	Hold	96,995	–	–	﹤0.01%	3170
2024 Q4	$167K	Buy	96,995 +79,940	+469%	+$192K	﹤0.01%	3146
2024 Q3	$42.3K	Sell	17,055 -16,594	-49%	-$45K	﹤0.01%	3393
2024 Q2	$81.4K	Buy	+33,649	New	+$107K	﹤0.01%	3180
2022 Q2	–	Sell	-15,501	Closed	-$61K	–	4115
2022 Q1	$61K	Buy	15,501 +9,677	+166%	+$52.6K	﹤0.01%	3768
2021 Q4	$39K	Buy	5,824 +306	+6%	+$3.36K	﹤0.01%	4023
2021 Q3	$82K	Buy	+5,518	New	+$91.8K	﹤0.01%	3966

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Deutsche Bank's ABOS Position: Q2 2025 in Review

Deutsche Bank sold out of Acumen Pharmaceuticals (ABOS) in Q2 2025, closing a stake of 96,995 shares — an estimated $107K sold.

Deutsche Bank first reported a position in ABOS in Q3 2021 and held it in 7 quarters. The position peaked at $167K in Q4 2024. 71 funds tracked by Wall St. Rank hold ABOS as of Q2 2025.

Deutsche Bank reported no remaining Acumen Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Deutsche Bank sold 96,995 Acumen Pharmaceuticals shares in Q2 2025, an estimated $107K.
Deutsche Bank first reported a position in Acumen Pharmaceuticals in Q3 2021 and held it in 7 quarters.
Deutsche Bank's Acumen Pharmaceuticals position peaked at $167K in Q4 2024.
71 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2025.

Based on Deutsche Bank's 13F filing for Q2 2025, filed 12 Aug 2025.